Trial Profile
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer - A Proof of Concept, Open Label Non-randomized Phase IIa Study. The AVETUXIRI Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms AVETUXIRI
- 24 Oct 2023 Results (n=55) characterizing the immune response for biomarker discovery through associated translational research presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results (n=57) assessing the efficacy and safety of Avelumab, cetuximab and irinotecan for the treatment of refractory microsatellite stable metastatic colorectal cancer, presented at the 48th European Society for Medical Oncology Congress.
- 07 Jun 2022 According to interim results presented at the 58th Annual Meeting of the American Society of Clinical Oncology, this study met its preliminary primary efficacy endpoint for continuation.